Theravance Biopharma Inc. (NASDAQ: TBPH) has recently garnered significant attention due to a series of notable insider transactions, varied analyst ratings, and fluctuating stock performance. These events offer deep insights into the current state and future trajectory of the company, presenting a
AstraZeneca has set the wheels in motion to significantly expand its biomanufacturing capacities with a $135 million investment in the Sweden Biomanufacturing Center in Södertälje. This venture marks the company's largest single investment in the facility since its inception in 2021, i
Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%
Theravance Biopharma Inc (NASDAQ: TBPH) has been navigating a complex landscape filled with mixed signals, affecting its market performance and generating varied sentiment among analysts and investors alike. This article delves into recent developments surrounding the company, including key
In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The
Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production
